Life Sciences

Life Sciences

P2Y 12-receptor antagonist - Novel antagonists of the P2Y12-receptor with antithrombotic effect

pdf

Angebotsbeschreibung

Ref.-Nr. 1526

Purinergic receptors have been in the focus of drug discovery for many years. Modulation of P2 receptors in platelets is of paramount importance in regulating platelet function, and, as a consequence, in controlling thrombotic diseases, which are the most common cause of morbidity and mortality in the Western world.

The P2Y12-receptor on blood platelets is the target of known antithrombotic drugs (e.g. clopidogrel). The receptor is therefore validated for this therapeutic use. Furthermore, the P2Y12-receptor is expressed in certain parts of the brain, which opens new routes for the treatment of neuroinflammatory and neurodegenerative diseases.

This invention provides novel antagonists of the P2Y12-receptor. The disclosed novel compounds show reversible and selective binding to the P2Y12-receptor. The molecules do not require bioactivation. Further the patent application discloses synthesis of the compounds with optimised product yield

Commercial Opportunities

We offer a patent license as well as a research collaboration with licensing option to innovative companies.

Current Status

Patent applications for the invention have been filed in Europe and North America.

Keywords: P2Y 12-receptor antagonist, antithombotic effect, platelet aggregation, neuroinflammatory and neurodegenerative diseases


bitte Kontaktieren Sie mich zu diesem angebot.

Kontakt

PROvendis GmbH · Schloßstr. 11 – 15
D – 45468 Mülheim an der Ruhr
T +49 (0)208 94105-0 · kontakt@provendis.info